Metabolism of aceclofenac in humans

Drug Metabolism and Disposition

Volumn 24, Issue 8, 1996, Pages 834-841

  Bort, R ^a,b   Ponsoda, X ^a,c   Carrasco, E ^b,d   Gomez Lechon M J ^a   Castell, J V ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Prodesfarma Research Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYACECLOFENAC; 5 HYDROXYACECLOFENAC; ACECLOFENAC; CYTOCHROME; DICLOFENAC; DRUG METABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFAPHENAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER CELL CULTURE; LIVER MICROSOME; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; HUMANS; HYDROXYLATION; ISOENZYMES; LIVER; MALE; MICROSOMES, LIVER; REFERENCE VALUES;

EID: 0029790413     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. P. G. Movilia: Evaluation of the analgesic activity and tolerability of aceclofenac in the treatment of post-episiotomy pain. Drugs Exp. Clin. Res. 15, 45-51 (1989).
2. M. Grau, J. Guasch, J. L. Montero, A. Felipe, E. Carrasco, and S. Julia: Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arneimittelforschung 41, 1265-1276 (1991).
3. M. Grau, J. L. Montero, J. Guasch, A. Felipe, E. Carrasco, and S. Julia: The pharmacological profile of aceclofenac, a new non-steroidal antiinflammatory and analgesic drug. Agents Actions Suppl. 32, 125-129 (1991).
4. G. Pasero, G. Ruju, R. Marcolongo, M. Senesi, U. Serni, A. Mannoni, S. Accardo, B. Seriolo, B. Colombo, G. C. Ligniere, G. Consoli, D. Desantis, S. Ferri, C. Amoresano, L. Frizziero, M. Reta, G. Giorgianni, U. Martorana, S. Termine, L. Mattara, M. Franceschini, P. Oriente, R. Scarpa, G. Perpignano, A. Bogliolo, G. Torri, F. Trotta, and F. Govoni: Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: a double-blind, controlled study. Curr. Ther. Res. Clin. Exp. 55, 833-842 (1994).
5. G. Torri, C. Vignati, E. Agrifoglio, M. Benvenuti, L. Ceciliani, B. F. Raschella, G. Letizia, U. Martorana, L. Tessari, G. Thovez, and A. Siclari: Aceclofenac versus piroxicam in the management of osteo-arthritis of the knee: a double-blind controlled study. Curr. Ther. Res. Clin. Exp. 55, 576-583 (1994).
6. J. T. Dingle: The effect of NSAID on human articular cartilage glycosaminoglycan synthesis. Eur. J. Rheumatol. Inflamm. 16, 47-52 (1996).
7. M. J. Gómez-Lechón, P. López, T. Donato, A. Montoya, A. Larrauri, P. Giménez, R. Trullenque, R. Fabra, and J. V. Castell: Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo. In Vitro Cell Dev. Biol. 26, 67-74 (1990).
8. A. R. Boobis, M. J. Brodie, G. C. Kahn, D. R. Fletcher, J. H. Saunders, and D. S. Davies: Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br. J. Clin. Pharmacol. 9, 11-19 (1980).
9. D. Sesardic, A. R. Boobis, S. Murray, J. Segura, R. De la Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
10. H. Raunio, T. Syngelmä, M. Pasanen, R. Juvonen, P. Honkakoski, M. A. Kairaluoma, E. A. Sotaniemi, M. A. Lang, and O. Pelkonen: Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem. Pharmacol. 37, 3889-3895 (1988).
11. T. Leemann, C. Transon, and P. Dayer: Cytochrome-P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 52, 29-34 (1993).
12. W. R. Brian, P. K. Srivastava, D. R. Umbenhauer, R. S. Lloyd, and F. P. Guengerich: Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993-4999 (1989).
13. T. Inaba, M. Jurima, W. A. Mahon, and W. Kalow: In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 13, 443-448 (1985).
14. R. Peter, R. G. Böcker, P. H. Beaune, N. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chloroxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
15. T. K. H. Chang, F. J. Gonzalez, and D. J. Waxman: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. 311, 437-442 (1994).
16. S. Murray and A. R. Boobis: An assay for paracetamol, produced by the O-deethylation of phenacetin in vitro, using gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biomed. Environ. Mass Spec. 13, 416-421 (1986).
17. A. Aitio: A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal. Biochem. 85, 488-491 (1978).
18. M. E. Veronese, P. I. Mackenzie, C. J. Doecke, M. E. McManus, J. O. Miners, and D. J. Birkett: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochem. Biophys. Res. Commun. 175, 1112-1118 (1991).
19. A. R. Boobis, S. Murray, G. C. Kahn, G. M. Robertz, and D. S. Davies: Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol. Pharmacol. 23, 474-481 (1983).
20. R. Peter, R. Bocker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
21. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36, 89-96 (1989).
22. H. K. Jajoo, I. A. Blair, L. J. Klunk, and R. F. Mayol: In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 20, 779-786 (1990).
23. M. P. Gascon and P. Dayer: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 41, 573-578 (1991).
24. A. E. M. Vickers, V. Fischer, S. Connors, R. L. Fisher, J. P. Baldeck, G. Maurer, and K. Brendel: Cyclosporin A metabolism in human liver, kidney and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab. Dispos. 20, 802-809 (1992).
25. A. D. Rodrigues: Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochem. Pharmacol. 48, 2147-2156 (1994).
26. B. Valles, C. D. Schiller, P. Coassolo, G. De Sousa, R. Wyss, D. Jaeck, A. Viger-Chougnet, and R. Rahmani: Metabolism of moforatene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab. Dispos. 23, 1051-1057 (1995).
27. M. T. Donato, M. J. Gómez-Lechón, and J. V. Castell: Effects of xenobiotics on monooxygenase activities in cultured human hepatocytes. Biochem. Pharmacol. 39, 1321-1326 (1990).
28. M. T. Donato, M. J. Gómez-Lechón, and J. V. Castell: Biotransformation of drugs by cultured hepatocytes. In "In Vitro Alternatives to Animal Pharmaco-Toxicology" (J. V. Castell and M. J. Gómez-Lechón, eds.), pp. 149-178. Farmaindustria, Barcelona, Spain, 1992.
29. M. T. Donato, J. V. Castell, and M. J. Gómez-Lechón: Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos. 23, 553-558 (1995).
30. TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp. Clin. Res. 19, 189-195 (1993).
31. M. E. Veronese, C. J. Doecke, P. I. Mackenzie, M. E. McManus, J. O. Miners, D. L. Rees, R. Gasser, U. A. Meyer, and D. J. Birkett: Site directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem. J. 289, 533-538 (1993).